Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

[1]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[4]  D. Cunningham,et al.  Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[5]  Y. Bang,et al.  LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer , 2017 .

[6]  J. Tabernero,et al.  616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB) , 2017 .

[7]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[8]  Z. Dai,et al.  Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis , 2017, OncoTargets and therapy.

[9]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Ajani,et al.  Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer , 2017, Clinical Cancer Research.

[11]  Y. Bang,et al.  A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Shah,et al.  KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. , 2017 .

[13]  P. Ascierto,et al.  Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. , 2017 .

[14]  R. Herbst,et al.  Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. , 2017 .

[15]  M. Shah,et al.  Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial , 2017, JAMA oncology.

[16]  Bingjin Li,et al.  Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis , 2017, PloS one.

[17]  J. Luke,et al.  Identification of T-cell-inflamed gastric adenocarcinoma in The Cancer Genome Atlas (TCGA). , 2017 .

[18]  I. Melero,et al.  Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells , 2017, Immunology and cell biology.

[19]  Burak Bilgin,et al.  Targeting the PD-1 pathway: a new hope for gastrointestinal cancers , 2017, Current medical research and opinion.

[20]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[21]  Xiaodong Zhu,et al.  Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study , 2016, Oncotarget.

[22]  O. Sonmez,et al.  Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study , 2016, American journal of therapeutics.

[23]  E. Smyth,et al.  Immunotherapy for Gastroesophageal Cancer , 2016, Journal of clinical medicine.

[24]  R. Kanthan,et al.  Gastric biomarkers: a global review , 2016, World Journal of Surgical Oncology.

[25]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[26]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[27]  R. Tollenaar,et al.  P-131An international patient-centered outcome measurement set for colorectal cancer , 2016 .

[28]  L. Rajdev,et al.  Current and emerging therapies in unresectable and recurrent gastric cancer. , 2016, World journal of gastroenterology.

[29]  Sung Sook Lee,et al.  Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. , 2016 .

[30]  H. Chung,et al.  Taxanes in the Treatment of Advanced Gastric Cancer , 2016, Molecules.

[31]  J. Schellens,et al.  Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study , 2016, Cancer.

[32]  G. Freeman,et al.  Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers , 2016, Oncotarget.

[33]  A. Bass,et al.  Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? , 2016, Nature Reviews Cancer.

[34]  H. Kourie,et al.  Metastatic gastric cancer treatment: Second line and beyond. , 2016, World journal of gastroenterology.

[35]  H. Kalthoff,et al.  PD-L1 is an independent prognostic predictor in gastric cancer of Western patients , 2016, Oncotarget.

[36]  Zongguang Zhou,et al.  Lessons Learned From a Case of Gastric Cancer After Liver Transplantation for Hepatocellular Carcinoma , 2016, Medicine.

[37]  C. Tournigand,et al.  Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[38]  Jun Wu,et al.  Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. , 2015, International journal of clinical and experimental pathology.

[39]  Jian Huang,et al.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[40]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Klempner,et al.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. , 2015, Journal of gastrointestinal oncology.

[42]  M. Postow.  Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[43]  H. Saito,et al.  Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery , 2015, Yonago acta medica.

[44]  Shufeng Zhou,et al.  Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer , 2015, Drug design, development and therapy.

[45]  K. Almhanna,et al.  Current status of novel agents in advanced gastroesophageal adenocarcinoma. , 2015, Journal of gastrointestinal oncology.

[46]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[48]  Johann A. Gagnon-Bartsch,et al.  Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas , 2014, Gut.

[49]  M. Ychou,et al.  Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[51]  N. Segal,et al.  1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[53]  I. D. de Vries,et al.  Molecular Pathways Molecular Pathways : The Immunogenic Effects of Platinum-Based Chemotherapeutics , 2014 .

[54]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[55]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  H. Yoshiji,et al.  Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo , 2013, Clinical and experimental immunology.

[57]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[58]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[59]  N. Boku.  HER2-positive gastric cancer , 2013, Gastric Cancer.

[60]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[61]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[62]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[63]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[64]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[65]  Chia-Der Lin,et al.  Increased programmed death‐ligand‐1 expression in human gastric epithelial cells in Helicobacter pylori infection , 2010, Clinical and experimental immunology.

[66]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[67]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  P. Stern,et al.  Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma , 2010, Clinical Cancer Research.

[69]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[72]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[73]  Chad A. LaGrange,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[74]  E. Tartour,et al.  Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.

[75]  Sang-Hoon Ahn,et al.  Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer , 2014, Gastric Cancer.

[76]  T. Vaughan,et al.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. , 2013, Seminars in radiation oncology.

[77]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.